Remicade Off-Label RA Campaign Cleared With Balancing Statement
Executive Summary
FDA has given the go-ahead to an off-label journal dissemination campaign for Centocor's Remicade for use in rheumatoid arthritis. FDA cleared the promotional effort in accordance with FDA Modernization Act Sec. 401 rules.